However, the company does not continue to train candidates.
Acerilin announced positive results from a late-stage study of its IL-17A inhibitor izokibep in hidradenitis suppurativa (HS), but said it will not proceed with clinical trials of the asset in this indication.
Estimated to affect approximately 1% of the population in most surveyed countries, HS is a chronic inflammatory skin disease that causes painful nodules and abscesses.
In a Phase 3 study, Izoquibep demonstrated statistically significant responses across multiple efficacy endpoints at week 12, with 33% of patients receiving Izoquibep 160 mg weekly achieving at least a 75% reduction in the total number of abscesses and inflammatory nodules (HiSCR75) compared to 21% of patients receiving placebo.
The results also showed that 25% and 22% of izoxalib-treated patients achieved HiSCR90 and HiSCR100, respectively, compared with 9% and 8%, respectively, in the placebo group.
The announcement comes shortly after the drug showed promising results in a Phase 2b/3 trial in psoriatic arthritis (PsA), a chronic inflammatory disease characterized by joint pain, stiffness and swelling.
Acerilin said it will complete its ongoing HS and PsA trials but will halt new investments in these indications. A Phase 2b/3 study of izokibep in uveitis will also continue to its primary endpoint, with topline data expected later this year.
Going forward, the company announced that it will prioritize the development of lonigtamab, an anti-IGF-1R monoclonal antibody being evaluated for the treatment of thyroid eye disease (TED).
